Evogene (EVGN) Cash from Discontinued Operations (2024 - 2026)
Evogene (EVGN) posted Cash from Discontinued Operations of 40000.0 for Q1 2026, up 128.57% sequentially from 140000.0 in Q4 2025, and up 104.16% YoY from 19592.25 in Q1 2025.
Evogene (EVGN) Cash from Discontinued Operations (2024 - 2026) Analysis & Trends
Evogene has reported Cash from Discontinued Operations for 3 years, with the latest figure at 40000.0 in Q1 2026.
- Quarterly Cash from Discontinued Operations rose 104.16% year-over-year to 40000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1715000.0 (changed N/A YoY) and the FY2025 annual result came in at 2115000.0, up 3.03% from the prior year.
- Cash from Discontinued Operations grew to 40000.0 in Q1 2026 per EVGN's latest filing, from 140000.0 in the prior quarter.
- Over five years, Cash from Discontinued Operations peaked at 40000.0 in Q1 2026 and troughed at 1035000.0 in Q4 2024.
- A 3-year average of 550000.0 and a median of 654000.0 in 2025 frame the typical range for Cash from Discontinued Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Discontinued Operations surged 86.47% in 2025, then surged 104.16% in 2026.
- Over 3 years, Cash from Discontinued Operations stood at 1035000.0 in 2024, then surged by 86.47% to 140000.0 in 2025, then soared by 128.57% to 40000.0 in 2026.
- According to Business Quant data, Cash from Discontinued Operations over the past three periods registered 40000.0, 140000.0, and 654000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 40,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40,000.00 |
| Mar 31, 2026 | 40,000.00 |
| Dec 31, 2025 | -140,000.00 |
| Dec 31, 2025 | -140,000.00 |
| Jun 30, 2025 | -654,000.00 |
| Jun 30, 2025 | -654,000.00 |
| Mar 31, 2025 | -961,000.00 |
| Mar 31, 2025 | -961,000.00 |
| Dec 31, 2024 | -1.04 Mn |
| Dec 31, 2024 | -1.04 Mn |